Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.67 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.47 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 10/20 | 0.46 |
| ▸ | CA12 | O43570 | 10/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952287 | 0.81 | CYP2A6 (1.00) | CYP2A6DYRK1ACA2CA12ALDH1A1 | |
| SCHEMBL632443 | 0.81 | CYP2A6 (1.00) | CYP2A6DYRK1ACA2CA12ALDH1A1 | |
| SCHEMBL27864617 | 0.78 | CA2 (0.57) | CYP2A6DYRK1ACA2CA12ENPP1 | |
| SCHEMBL2036162 | 0.77 | CA2 (0.60) | CYP2A6DYRK1ACA2CA12ENPP1 | |
| SCHEMBL11770226 | 0.76 | TRIM24 (0.71) | CYP2A6DYRK1ATRIM24TRIM33CA2 | |
| SCHEMBL346974 | 0.76 | TRIM24 (0.64) | CYP2A6DYRK1ATRIM24TRIM33CA2 | |
| SCHEMBL28744555 | 0.76 | CA2 (0.60) | CYP2A6DYRK1ACA2CA12ENPP1 | |
| SCHEMBL20180340 | 0.75 | DYRK1A (0.53) | CYP2A6DYRK1ACA2CA12ENPP1 | |
| SCHEMBL27621710 | 0.74 | TRIM24 (0.68) | CYP2A6DYRK1ATRIM24TRIM33CA2 | |
| SCHEMBL10227496 | 0.74 | TRIM24 (0.54) | CYP2A6TRIM24TRIM33CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1731505-B1 | ALKOXYPHENYLPROPANOIC ACID DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2015-01-14 | — | — | EP | disclosed |
| EP-1731505-B1 | ALKOXYPHENYLPROPANOIC ACID DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2015-01-14 | — | — | EP | disclosed |
| EP-2253315-A1 | Alkoxyphenylpropanoic acid derivatives | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| EP-2253315-A1 | Alkoxyphenylpropanoic acid derivatives | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| US-7820837-B2 | ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7820837-B2 | ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7820837-B2 | ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7517910-B2 | Alkoxyphenylpropanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-7517910-B2 | Alkoxyphenylpropanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-7517910-B2 | Alkoxyphenylpropanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070213364-A1 | Alkoxyphenylpropanoic Acid Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070213364-A1 | Alkoxyphenylpropanoic Acid Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070213364-A1 | Alkoxyphenylpropanoic Acid Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-09-13 | — | — | US | disclosed |
| EP-1731505-A1 | ALKOXYPHENYLPROPANOIC ACID DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2006-12-13 | — | — | EP | disclosed |
| US-20060258722-A1 | Condensed ring compound | TAKEDA PHARMACEUTICAL COMPANY., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| EP-1630152-A1 | CONDENSED RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2006-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213364-A1 | Alkoxyphenylpropanoic Acid Derivatives | GPR119, FFAR1, GPR55 | CYP2A6 725/4885DYRK1A 3400/4885TRIM24 2011/4885 |
| US-20060258722-A1 | Condensed ring compound | GPR119, GLP1R, GCGR | CYP2A6 2475/4885DYRK1A 2833/4885TRIM24 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.